<DOC>
	<DOCNO>NCT00215202</DOCNO>
	<brief_summary>The use Iressa result great 20 % response rate patient nonresectable adrenocortical cancer previously treat one form systemic therapy ( either Mitotane chemotherapy ) .</brief_summary>
	<brief_title>Phase II Trial ZD1839 ( Iressa ) Patients With Nonresectable Adrenocortical Carcinoma ( ACC )</brief_title>
	<detailed_description>Adrenocortical carcinoma rare cancer incidence 1.5 2 per million people United States . Surgery potentially curative option . Current systemic therapy , either Mitotane chemotherapy , typically give response rate 20 % less . This study design see newer target therapy , Iressa , may benefit patient fatal disease . Patients nonresectable adrenocortical cancer progress least one form systemic therapy ( Mitotane chemotherapy ) give Iressa 250 mg mouth daily disease progression . This standard two-stage Phase II clinical trial . Eighteen patient measurable disease enrol first stage . If least one responder , additional nine patient measurable disease enrol total 27 patient measurable disease . Up six patient without measurable disease may enrol point study . Iressa provide free study participant .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adrenocortical Carcinoma</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Subject must able provide inform consent Subject must 18 year age old Subject must histologically confirm ACC Department Pathology Dartmouth Hitchcock Medical Center Subject must inoperable disease Subject must receive form systemic therapy prior enrol study know severe hypersensitivity Iressa coexist malignancy diagnose within last five year except basal cell cancer cervical cancer situ unresolved CTC grade 2 toxicity previous anticancer therapy ( except alopecia ) absolute neutrophil count le 1.5 x 1,000,000,000 per liter platelet less 20 x 1,000,000,000 per liter severe uncontrolled systemic disease pregnancy\breastfeeding woman fertile willing practice abstinence contraception use phenytoin , carbamazepine , rifampicin , barbiturate , St. John 's Wort treatment nonapproved investigational drug within 28 day Day 1 study treatment prior use ZD1839 ( Iressa ) antiEGFR therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Adrenocortical Cancer</keyword>
	<keyword>Iressa</keyword>
	<keyword>Adrenal Cancer</keyword>
</DOC>